159 related articles for article (PubMed ID: 29019897)
1. Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors.
Lin LY; Yeh YC; Chu CH; Won JGS; Shyr YM; Chao Y; Li CP; Wang SE; Chen MH
Medicine (Baltimore); 2017 Oct; 96(41):e8262. PubMed ID: 29019897
[TBL] [Abstract][Full Text] [Related]
2. Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer.
Chang Y; Niu W; Lian PL; Wang XQ; Meng ZX; Liu Y; Zhao R
World J Gastroenterol; 2016 Jun; 22(23):5422-9. PubMed ID: 27340359
[TBL] [Abstract][Full Text] [Related]
3. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.
Zhou B; Fang B; Yan S; Wang W
Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692
[TBL] [Abstract][Full Text] [Related]
5. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer.
El Behery MM; Seksaka MA; Ibrahiem MA; Saleh HS; El Alfy Y
Arch Gynecol Obstet; 2013 Dec; 288(6):1371-6. PubMed ID: 23708323
[TBL] [Abstract][Full Text] [Related]
7. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
[TBL] [Abstract][Full Text] [Related]
8. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
9. A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion.
Miao Y; Zong M; Jiang T; Yuan X; Guan S; Wang Y; Zhou D
Pituitary; 2016 Apr; 19(2):194-201. PubMed ID: 26809958
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characterization and Treatment of Pancreatic Neuroendocrine Tumors.
De Jesus-Acosta AMC
Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914198
[No Abstract] [Full Text] [Related]
11. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Klieser E; Urbas R; Stättner S; Primavesi F; Jäger T; Dinnewitzer A; Mayr C; Kiesslich T; Holzmann K; Di Fazio P; Neureiter D; Swierczynski S
Hum Pathol; 2017 Jul; 65():41-52. PubMed ID: 28235630
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy.
Arslan B; Onuk Ö; Hazar İ; Aydın M; Çilesiz NC; Eroglu A; Nuhoglu B
Tumori; 2017 Mar; 103(2):204-208. PubMed ID: 27470607
[TBL] [Abstract][Full Text] [Related]
13. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
14. Biological and clinical implications of endocan in gastric cancer.
Zhao W; Sun M; Li S; Wang Y; Liu J
Tumour Biol; 2014 Oct; 35(10):10043-9. PubMed ID: 25012244
[TBL] [Abstract][Full Text] [Related]
15. Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors.
Chen MH; Yeh YC; Shyr YM; Jan YH; Chao Y; Li CP; Wang SE; Tzeng CH; Chang PM; Liu CY; Chen MH; Hsiao M; Huang CY
J Gastroenterol; 2013 Jan; 48(1):101-8. PubMed ID: 22706573
[TBL] [Abstract][Full Text] [Related]
16. Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors.
Sato S; Tsuchikawa T; Nakamura T; Sato N; Tamoto E; Okamura K; Shichinohe T; Hirano S
Oncol Rep; 2014 Dec; 32(6):2753-9. PubMed ID: 25310565
[TBL] [Abstract][Full Text] [Related]
17. Endocan expression correlated with poor survival in human hepatocellular carcinoma.
Huang GW; Tao YM; Ding X
Dig Dis Sci; 2009 Feb; 54(2):389-94. PubMed ID: 18592377
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.
Xu SS; Xu HX; Wang WQ; Li S; Li H; Li TJ; Zhang WH; Liu L; Yu XJ
World J Gastroenterol; 2019 Nov; 25(41):6248-6257. PubMed ID: 31749595
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor.
Nanno Y; Matsumoto I; Zen Y; Otani K; Uemura J; Toyama H; Asari S; Goto T; Ajiki T; Okano K; Suzuki Y; Takeyama Y; Fukumoto T; Ku Y
Ann Surg Oncol; 2017 Apr; 24(4):1127-1133. PubMed ID: 27822631
[TBL] [Abstract][Full Text] [Related]
20. Do morphologic characteristics play a role in nodal metastatic progression of well-differentiated pancreatic neuroendocrine tumors?
Ugras N; Hasdemir S; Yerci Ö; Taşar P; Dündar HZ; Macunluoğlu AC
Tumori; 2021 Feb; 107(1):80-85. PubMed ID: 32705937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
